|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Doorn R, Van Horssen J, Verzijl D,
Witte M, Ronken E, Van Het HB, Lakeman K, Dijkstra CD, Van Der Valk
P, Reijerkerk A, et al: Sphingosine 1-phosphate receptor 1 and 3
are upregulated in multiple sclerosis lesions. Glia. 58:1465–1476.
2010. View Article : Google Scholar
|
|
3
|
Zhang G, Yang L, Kim GS, Ryan K, Lu S,
O'Donnell RK, Spokes K, Shapiro N, Aird WC, Kluk MJ, et al:
Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in
acute vascular inflammation. Blood. 122:443–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baldari CT: The hematopoietic oncoprotein
FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma
by repressing S1PR2 signaling. Blood. 127:1380–1381. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green JA and Cyster JG: S1PR2 links
germinal center confinement and growth regulation. Immunol Rev.
247:36–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Green JA, Suzuki K, Cho B, Willison LD,
Palmer D, Allen CD, Schmidt TH, Xu Y, Proia RL, Coughlin SR and
Cyster JG: The sphingosine 1-phosphate receptor S1P2
maintains the homeostasis of germinal center B cells and promotes
niche confinement. Nat Immunol. 12:672–680. 2011. View Article : Google Scholar
|
|
7
|
Sánchez DI, González-Fernández B,
San-Miguel B, de Urbina JO, Crespo I, González-Gallego J and Tuñón
MJ: Melatonin prevents deregulation of the sphingosine
kinase/sphingosine 1-phosphate signaling pathway in a mouse model
of diethylnitrosamine-induced hepatocellular carcinoma. J Pineal
Res. 62:e123692017. View Article : Google Scholar
|
|
8
|
Higashi K, Matsuzaki E, Hashimoto Y,
Takahashi-Yanaga F, Takano A, Anan H, Hirata M and Nishimura F:
Sphingosine-1-phosphate/S1PR2-mediated signaling triggers Smad1/5/8
phosphorylation and thereby induces Runx2 expression in
osteoblasts. Bone. 93:1–11. 2016. View Article : Google Scholar
|
|
9
|
Nagahashi M, Yuza K, Hirose Y, Nakajima M,
Ramanathan R, Hait NC, Hylemon PB, Zhou H, Takabe K and Wakai T:
The roles of bile acids and sphingosine-1-phosphate signaling in
the hepatobiliary diseases. J Lipid Res. 57:1636–1643. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shida D, Inoue S, Yoshida Y, Kodaka A,
Tsuji T and Tsuiji M: Sphingosine kinase 1 is upregulated with
lysophosphatidic acid receptor 2 in human colorectal cancer. World
J Gastroenterol. 22:2503–2511. 2016. View Article : Google Scholar
|
|
11
|
Spiegel S and Milstien S:
Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol
Cell Bio. 4:397–407. 2003. View
Article : Google Scholar
|
|
12
|
Pyne S and Pyne NJ: Sphingosine
1-phosphate signalling in mammalian cells. Biochem J. 349:385–402.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gonzalezcabrera PJ, Brown S, Studer SM and
Rosen H: S1P signaling: New therapies and opportunities. F1000
Prime Reports. 6:1092014.PubMed/NCBI
|
|
14
|
Pyne NJ and Pyne S: Sphingosine
1-phosphate and cancer. Nat Rev Cancer. 10:489–503. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pyne NJ, Mcnaughton M, Boomkamp S,
Macritchie N, Evangelesti C, Martelli AM, Jiang HR, Ubhi S and Pyne
S: Role of sphingosine 1-phosphate receptors, sphingosine kinases
and sphingosine in cancer and inflammation. Adv Biol Regul.
60:151–159. 2015. View Article : Google Scholar
|
|
16
|
Sukocheva OA, Furuya H, Ng ML, Friedemann
M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova
ME, Mangoni AA, et al: Sphingosine kinase and
sphingosine-1-phosphate receptor signaling pathway in inflammatory
gastrointestinal disease and cancers: A novel therapeutic target.
Pharmacol Ther. 207:1074642020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okamoto H, Takuwa N, Gonda K, Okazaki H,
Chang K, Yatomi Y, Shigematsu H and Takuwa Y: EDG1 is a functional
sphingosine-1-phosphate receptor that is linked via a Gi/o to
multiple signaling pathways, including phospholipase C activation,
Ca2+ mobilization, Ras-mitogen-activated protein kinase activation,
and adenylate cyclase inhibition. J Biol Chem. 273:27104–27110.
1998. View Article : Google Scholar
|
|
18
|
Hannun YA and Obeid LM: Principles of
bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol
Cell Bio. 9:139–150. 2008. View
Article : Google Scholar
|
|
19
|
Ng ML, Wadham C and Sukocheva OA: The role
of sphingolipid signalling in diabetesassociated pathologies
(Review). Int J Mol Med. 39:243–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arikawa K, Takuwa N, Yamaguchi H, Sugimoto
N, Kitayama J, Nagawa H, Takehara K and Takuwa Y: Ligand-dependent
inhibition of B16 melanoma cell migration and invasion via
endogenous S1P2 G protein-coupled receptor. Requirement of
inhibition of cellular RAC activity. J Biol Chem. 278:32841–32851.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang J, Nagahashi M, Kim EY, Harikumar
KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM and Avni D:
Sphingosine-1-phosphate links persistent STAT3 activation, chronic
intestinal inflammation, and development of colitis-associated
cancer. Cancer Cell. 23:107–120. 2013. View Article : Google Scholar
|
|
22
|
Du W, Takuwa N, Yoshioka K, Okamoto Y,
Gonda K, Sugihara K, Fukamizu A, Asano M and Takuwa Y: S1P(2), the
G protein-coupled receptor for sphingosine-1-phosphate, negatively
regulates tumor angiogenesis and tumor growth in vivo in mice.
Cancer Res. 70:772–781. 2010. View Article : Google Scholar
|
|
23
|
Watson C, Long JS, Orange C, Tannahill CL,
Mallon E, Mcglynn LM, Pyne S, Pyne NJ and Edwards J: O-56 High
expression of sphingosine 1-phosphate receptors, S1P 1 and S1P 3,
sphingosine kinase 1 and ERK-1/2 is associated with development of
tamoxifen resistance in ER positive breast cancer patients. Eur J
Cancer Suppl. 8:212010. View Article : Google Scholar
|
|
24
|
Yoshida Y, Nakada M, Harada T, Tanaka S,
Furuta T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y and Hamada J:
The expression level of sphingosine-1-phosphate receptor type 1 is
related to MIB-1 labeling index and predicts survival of
glioblastoma patients. J Neurooncol. 98:41–47. 2010. View Article : Google Scholar
|
|
25
|
Kothapalli R, Kusmartseva I and Loughran
TP: Characterization of a human sphingosine-1-phosphate receptor
gene (S1P 5) and its differential expression in LGL leukemia.
Biochim Biophys Acta. 1579:117–123. 2002. View Article : Google Scholar
|
|
26
|
Cattoretti G, Mandelbaum J, Lee N, Chaves
AH, Mahler AM, Chadburn A, Dallafavera R, Pasqualucci L and
Maclennan AJ: Targeted disruption of the S1P2 sphingosine
1-phosphate receptor gene leads to diffuse large B-cell lymphoma
formation. Cancer Res. 69:8686–8692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Flori M, Schmid CA, Sumrall ET, Tzankov A,
Law CW, Robinson MD and Muller A: The hematopoietic oncoprotein
FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma
by repressing S1PR2 signaling. Blood. 127:1438–1448. 2016.
View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawamori T, Kaneshiro T, Okumura M,
Maalouf S, Uflacker A, Bielawski J, Hannun YA and Obeid LM: Role
for sphingosine kinase 1 in colon carcinogenesis. FASEB J.
23:405–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang
S, Liu L, Chen T, Li J, Tu H and He X: Sphingosine kinase 1
promotes tumour cell migration and invasion via the S1P/EDG1 axis
in hepatocellular carcinoma. Liver Int. 32:331–338. 2012.
View Article : Google Scholar
|
|
31
|
Terashita T, Kobayashi K, Nagano T, Kawa
Y, Tamura D, Nakata K, Yamamoto M, Tachihara M, Kamiryo H and
Nishimura Y: Administration of JTE013 abrogates experimental asthma
by regulating proinflammatory cytokine production from bronchial
epithelial cells. Respir Res. 17:1462016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang X, Wang W, Ji XY, Ritter JK and Li
N: Knockout of sphingosine kinase 1 attenuates renal fibrosis in
unilateral ureteral obstruction model. Am J Nephrol. 50:196–203.
2019. View Article : Google Scholar
|
|
33
|
Nuno DW and Lamping KG: Dietary fatty acid
saturation modulates sphingosine-1-phosphate-mediated vascular
function. J Diabetes Res. 2019:23542742019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Salas A, Ponnusamy S, Senkal CE,
Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD,
Smith C, Gault CR, et al: Sphingosine kinase-1 and sphingosine
1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug
resistance by modulation of protein phosphatase 2A. Blood.
117:5941–5952. 2011. View Article : Google Scholar
|
|
35
|
Jozefczuk E, Nosalski R, Saju B, Crespo E,
Szczepaniak P, Guzik TJ and Siedlinski M: Cardiovascular effects of
pharmacological targeting of sphingosine kinase 1. Hypertension.
75:383–392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kunkel GT, Maceyka M, Milstien S and
Spiegel S: Targeting the sphingosine-1-phosphate axis in cancer,
inflammation and beyond. Nat Rev Drug Discov. 12:688–702. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perla AS, Fratini L, Cardoso PS, de Farias
CB, Da CJM and Roesler R: Fingolimod (FTY720) reduces viability and
survival and increases histone H3 acetylation in medulloblastoma
cells. Pediatr Hematol Oncol. 37:170–175. 2020. View Article : Google Scholar
|
|
38
|
Pyne S and Pyne NJ: New Perspectives on
the Role of Sphingosine 1-Phosphate in Cancer. Sphingolipids in
Disease. Handbook of Experimental Pharmacology. Gulbins E and
Petrache I: 216. Springer; Vienna: pp. 55–71. 2013, View Article : Google Scholar
|
|
39
|
Beach JA, Aspuria PJ, Cheon DJ, Lawrenson
K, Agadjanian H, Walsh CS, Karlan BY and Orsulic S: Sphingosine
kinase 1 is required for TGF-beta mediated
fibroblastto-myofibroblast differentiation in ovarian cancer.
Oncotarget. 7:4167–4182. 2016. View Article : Google Scholar
|
|
40
|
Shida D, Takabe K, Kapitonov D, Milstien S
and Spiegel S: Targeting SphK1 as a new strategy against cancer.
Curr Drug Targets. 9:662–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen MH, Yen CC, Cheng CT, Wu RC, Huang
SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, et al:
Identification of SPHK1 as a therapeutic target and marker of poor
prognosis in cholangiocarcinoma. Oncotarget. 6:23594–23608. 2015.
View Article : Google Scholar
|
|
42
|
Patmanathan SN, Johnson SP, Lai SL, Bernam
SP, Lopes V, Wei W, Ibrahim MH, Torta F, Narayanaswamy P and Wenk
MR: Aberrant expression of the S1P regulating enzymes, SPHK1 and
SGPL1, contributes to a migratory phenotype in OSCC mediated
through S1PR2. Sci Rep. 6:256502016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ruckhäberle E, Rody A, Engels K, Gaetje R,
von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U,
Karn T and Kaufmann M: Microarray analysis of altered sphingolipid
metabolism reveals prognostic significance of sphingosine kinase 1
in breast cancer. Breast Cancer Res Treat. 112:41–52. 2008.
View Article : Google Scholar
|
|
44
|
Furuya H, Tamashiro PM, Shimizu Y, Iino K,
Peres R, Chen R, Sun Y, Hannun YA, Obeid LM and Kawamori T:
Sphingosine Kinase 1 expression in peritoneal macrophages is
required for colon carcinogenesis. Carcinogenesis. 38:1218–1227.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Furuya H, Shimizu Y, Tamashiro PM, Iino K,
Bielawski J, Chan O, Pagano I and Kawamori T: Sphingosine kinase 1
expression enhances colon tumor growth. J Transl Med. 15:1202017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Weigert A, Olesch C and Brune B:
Sphingosine-1-Phosphate and macrophage biology-how the sphinx tames
the big eater. Front Immunol. 10:17062019. View Article : Google Scholar
|
|
47
|
Andrieu G, Ledoux A, Branka S, Bocquet M,
Gilhodes J, Walzer T, Kasahara K, Inagaki M, Sabbadini RA,
Cuvillier O and Hatzoglou A: Sphingosine 1-phosphate signaling
through its receptor S1P5 promotes chromosome segregation and
mitotic progression. Sci Signal. 10:eaah40072017. View Article : Google Scholar
|
|
48
|
Suh JH and Saba JD:
Sphingosine-1-phosphate in inflammatory bowel disease and
colitis-associated colon cancer: The fat's in the fire. Transl
Cancer Res. 4:469–483. 2015.PubMed/NCBI
|
|
49
|
Wang C, Mao J, Redfield S, Mo Y, Lage JM
and Zhou X: Systemic distribution, subcellular localization and
differential expression of sphingosine-1-phosphate receptors in
benign and malignant human tissues. Exp Mol Pathol. 97:259–265.
2014. View Article : Google Scholar
|
|
50
|
Herr DR, Reolo MJ, Peh YX, Wang W, Lee CW,
Rivera R, Paterson IC and Chun J: Sphingosine 1-phosphate receptor
2 (S1P2) attenuates reactive oxygen species formation and inhibits
cell death: Implications for otoprotective therapy. Sci Rep.
6:245412016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Brinkmann V, Billich A, Baumruker T,
Heining P, Schmouder R, Francis G, Aradhye S and Burtin P:
Fingolimod (FTY720): Discovery and development of an oral drug to
treat multiple sclerosis. Nat Rev Drug Discov. 9:883–897. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Barthelemy C, Barry AO, Twyffels L and
Andre B: FTY720-induced endocytosis of yeast and human amino acid
transporters is preceded by reduction of their inherent activity
and TORC1 inhibition. Sci Rep. 7:138162017. View Article : Google Scholar : PubMed/NCBI
|
